467 related articles for article (PubMed ID: 35439677)
1. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis.
Xiao Y; Bi M; Guo H; Li M
EBioMedicine; 2022 May; 79():104001. PubMed ID: 35439677
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective.
Yang Z; Guan F; Bronk L; Zhao L
Pharmacol Ther; 2024 Feb; 254():108591. PubMed ID: 38286161
[TBL] [Abstract][Full Text] [Related]
3. Cancer biomarker discovery and translation: proteomics and beyond.
Hristova VA; Chan DW
Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
[TBL] [Abstract][Full Text] [Related]
4. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients.
Zhang L; Luo M; Yang H; Zhu S; Cheng X; Qing C
J Ovarian Res; 2019 Feb; 12(1):19. PubMed ID: 30786925
[TBL] [Abstract][Full Text] [Related]
6. A Detailed Catalogue of Multi-Omics Methodologies for Identification of Putative Biomarkers and Causal Molecular Networks in Translational Cancer Research.
Vlachavas EI; Bohn J; Ückert F; Nürnberg S
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802234
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy for ovarian cancer using circulating tumor cells: Recent advances on the path to precision medicine.
Yang J; Cheng S; Zhang N; Jin Y; Wang Y
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188660. PubMed ID: 34800546
[TBL] [Abstract][Full Text] [Related]
8. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
9. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
[TBL] [Abstract][Full Text] [Related]
10. From bio-molecular and technology innovations to clinical practice: focus on ovarian cancer.
Legge F; Ferrandina G; Scambia G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii46-8. PubMed ID: 16760291
[TBL] [Abstract][Full Text] [Related]
11. Urinary interleukin-1β levels among gynecological patients.
Woolery KT; Hoffman MS; Kraft J; Nicosia SV; Kumar A; Kruk PA
J Ovarian Res; 2014 Nov; 7():104. PubMed ID: 25403235
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
[TBL] [Abstract][Full Text] [Related]
13. "Omics" in oral cancer: New approaches for biomarker discovery.
Rai V; Mukherjee R; Ghosh AK; Routray A; Chakraborty C
Arch Oral Biol; 2018 Mar; 87():15-34. PubMed ID: 29247855
[TBL] [Abstract][Full Text] [Related]
14. A prognostic prediction model for ovarian cancer using a cross-modal view correlation discovery network.
Wang H; Han X; Ren J; Cheng H; Li H; Li Y; Li X
Math Biosci Eng; 2024 Jan; 21(1):736-764. PubMed ID: 38303441
[TBL] [Abstract][Full Text] [Related]
15. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.
Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483
[TBL] [Abstract][Full Text] [Related]
16. Omics sciences and precision medicine in prostate cancer.
Medori MC; Micheletti C; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Bernini A; Fulcheri E; Calogero AE; Cannarella R; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):95-103. PubMed ID: 37994753
[TBL] [Abstract][Full Text] [Related]
17. Novel Approaches in Ovarian Cancer Research against Heterogeneity, Late Diagnosis, Drug Resistance, and Transcoelomic Metastases.
Erol A; Niemira M; Krętowski AJ
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31146417
[TBL] [Abstract][Full Text] [Related]
18. Using knowledge-driven genomic interactions for multi-omics data analysis: metadimensional models for predicting clinical outcomes in ovarian carcinoma.
Kim D; Li R; Lucas A; Verma SS; Dudek SM; Ritchie MD
J Am Med Inform Assoc; 2017 May; 24(3):577-587. PubMed ID: 28040685
[TBL] [Abstract][Full Text] [Related]
19. Ovarian Cancer Biomarkers: Moving Forward in Early Detection.
Bonifácio VDB
Adv Exp Med Biol; 2020; 1219():355-363. PubMed ID: 32130708
[TBL] [Abstract][Full Text] [Related]
20. Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction.
Kim D; Shin H; Sohn KA; Verma A; Ritchie MD; Kim JH
Methods; 2014 Jun; 67(3):344-53. PubMed ID: 24561168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
